Mahendra G. Shah
Managing Director @ Vivo Capital
Cupertino, United States
Mahendra G. Shah is a Series A investor at Vivo Capital in Cupertino focused on Health Care and Biotechnology. Mahendra G. Shah, Ph.D. is a highly successful pharmaceutical entrepreneur and executive. From September 2005 to December 2009, he was the founder, chairman and CEO of NextWave Pharmaceuticals, a pediatric focused specialty pharmaceutical company. From 1993 to May 2003 he was the chairman and CEO of First Horizon Pharmaceuticals, a publicly tradedspecialty pharmaceutical company, where he raised over $200 million and built a very profitable company before it was was sold to Shionogi Pharmaceuticals for $1.4 billion. From 1991 to October 1999, he was vice president of E. J. Financial Enterprises, inc., which manages a fund that invests in healthcare companies. He previously served on the boards of Unimed Pharmaceuticals (UMED), Introgen Therapeutics (INGN), Inpharmakon, Protomed, Structural Bioinformatics, and Zarix. From 1987 to 1991 he was the senior director of new business development with Fujisawa USA (Astellas). Prior to that time he worked in various scientific and management positions with Schering-Plough and Bristol Myers-Squibb. Dr. Shah received his Ph.D. in industrial pharmacy from St. John’s University and his Bachelor’s and Master’s Degree in Pharmacy from L.M. College of Pharmacy in Gujarat, India.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Mahendra G. Shah invests in
Stages Mahendra G. Shah invests in
Countries Mahendra G. Shah invests in
Investment Focus
Industry
- Health Care 2 (100%)
- Biotechnology 2 (100%)
- Genetics 1 (50%)
- Therapeutics 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cerebral Therapeutics
|
Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. | $3M / Series A / Jun 20, 2018 | |
Homology Medicines
|
Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virusvectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. | $83.5M / Series B / Aug 01, 2017 |
Co-Investors
About Vivo Capital
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Vivo Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gaurav Aggarwal
Managing Director
|
|||
|
Mahendra G. Shah
Managing Director
|
|||
Michael Chang
Managing Partner
|
|||
Shan Fu
Managing Partner, Co-CEO, and CEO of Asia Pacific
|
|||
Chloe Zhang
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Mahendra G. Shah invest in?
Mahendra G. Shah invests primarily in Health Care, Biotechnology and Genetics startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Mahendra G. Shah last invest?
The most recent investment recorded for Mahendra G. Shah closed in Jun 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
